Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Shares Down 5.3% – Here’s Why

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) dropped 5.3% during trading on Thursday . The stock traded as low as $4.79 and last traded at $4.83. 249,718 shares traded hands during trading, an increase of 31% from the average daily volume of 190,897 shares. The stock had previously closed at $5.10.

Wall Street Analyst Weigh In

Separately, Zacks Research upgraded shares of Armata Pharmaceuticals to a “hold” rating in a research note on Monday, May 18th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, Armata Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $15.00.

Armata Pharmaceuticals Stock Performance

The stock has a market cap of $177.31 million, a P/E ratio of -0.62 and a beta of 1.26. The business’s 50-day moving average price is $7.55 and its 200-day moving average price is $8.44.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) last released its earnings results on Wednesday, May 13th. The company reported ($3.16) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($2.78). The company had revenue of $0.79 million during the quarter, compared to the consensus estimate of $0.74 million. As a group, equities research analysts expect that Armata Pharmaceuticals, Inc. will post -1.88 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in ARMP. Bank of America Corp DE increased its holdings in Armata Pharmaceuticals by 233.2% in the 1st quarter. Bank of America Corp DE now owns 11,714 shares of the company’s stock worth $120,000 after acquiring an additional 8,198 shares in the last quarter. Jane Street Group LLC purchased a new position in Armata Pharmaceuticals during the fourth quarter valued at approximately $108,000. Millennium Management LLC bought a new position in shares of Armata Pharmaceuticals in the fourth quarter worth approximately $164,000. OMERS ADMINISTRATION Corp bought a new position in shares of Armata Pharmaceuticals in the fourth quarter worth approximately $177,000. Finally, SeaCrest Wealth Management LLC boosted its position in shares of Armata Pharmaceuticals by 17.3% in the fourth quarter. SeaCrest Wealth Management LLC now owns 40,988 shares of the company’s stock worth $274,000 after purchasing an additional 6,034 shares during the period. 3.57% of the stock is currently owned by institutional investors.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company’s proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.

Armata’s pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens.